Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Positron emission tomography in the diagnosis and staging of lung cancer : a systematic, quantitative review. / Fischer, B M; Mortensen, J; Højgaard, L.

In: Lancet Oncology, Vol. 2, No. 11, 11.2001, p. 659-66.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Fischer, BM, Mortensen, J & Højgaard, L 2001, 'Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review', Lancet Oncology, vol. 2, no. 11, pp. 659-66. https://doi.org/10.1016/S1470-2045(01)00555-1

APA

Fischer, B. M., Mortensen, J., & Højgaard, L. (2001). Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. Lancet Oncology, 2(11), 659-66. https://doi.org/10.1016/S1470-2045(01)00555-1

Vancouver

Fischer BM, Mortensen J, Højgaard L. Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. Lancet Oncology. 2001 Nov;2(11):659-66. https://doi.org/10.1016/S1470-2045(01)00555-1

Author

Fischer, B M ; Mortensen, J ; Højgaard, L. / Positron emission tomography in the diagnosis and staging of lung cancer : a systematic, quantitative review. In: Lancet Oncology. 2001 ; Vol. 2, No. 11. pp. 659-66.

Bibtex

@article{beae9232e87f44cca66ca66bef9ac9b2,
title = "Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review",
abstract = "Lung cancer is the cause of 32{\%} of all male cancer deaths and 25{\%} of all female cancer deaths. Because the prognosis depends on early diagnosis and staging, continuous evaluation of the diagnostic tools available is important. The aim of this study was to assess the diagnostic value of dedicated positron emission tomography (PET) and gamma-camera PET in the diagnostic investigation of non-small-cell lung cancer (NSCLC). A systematic literature search was carried out in the MEDLINE and EMBASE databases and the Cochrane Controlled Trials Register. We identified 55 original works on the diagnostic performance of PET with fluorodeoxyglucose in the investigation of NSCLC. For diagnosis of NSCLC, the mean sensitivities and specificities were, respectively, 0.96 (SE 0.01) and 0.78 (0.03) for dedicated PET, and 0.92 (0.04) and 0.86 (0.04) for gamma-camera PET. In the mediastinal staging of NSCLC, the results were 0.83 (0.02) and 0.96 (0.01) for dedicated PET and 0.81 (0.04) and 0.95 (0.02) for ganuna-camera PET. We conclude that dedicated PET could be a valuable tool in the diagnosis and staging of NSCLC. However, studies of populations with a lower prevalence of NSCLC are recommended.",
keywords = "Aged, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Sensitivity and Specificity, Tomography, Emission-Computed, Journal Article, Review",
author = "Fischer, {B M} and J Mortensen and L H{\o}jgaard",
year = "2001",
month = "11",
doi = "10.1016/S1470-2045(01)00555-1",
language = "English",
volume = "2",
pages = "659--66",
journal = "Lancet Oncology",
issn = "1470-2045",
publisher = "TheLancet Publishing Group",
number = "11",

}

RIS

TY - JOUR

T1 - Positron emission tomography in the diagnosis and staging of lung cancer

T2 - a systematic, quantitative review

AU - Fischer, B M

AU - Mortensen, J

AU - Højgaard, L

PY - 2001/11

Y1 - 2001/11

N2 - Lung cancer is the cause of 32% of all male cancer deaths and 25% of all female cancer deaths. Because the prognosis depends on early diagnosis and staging, continuous evaluation of the diagnostic tools available is important. The aim of this study was to assess the diagnostic value of dedicated positron emission tomography (PET) and gamma-camera PET in the diagnostic investigation of non-small-cell lung cancer (NSCLC). A systematic literature search was carried out in the MEDLINE and EMBASE databases and the Cochrane Controlled Trials Register. We identified 55 original works on the diagnostic performance of PET with fluorodeoxyglucose in the investigation of NSCLC. For diagnosis of NSCLC, the mean sensitivities and specificities were, respectively, 0.96 (SE 0.01) and 0.78 (0.03) for dedicated PET, and 0.92 (0.04) and 0.86 (0.04) for gamma-camera PET. In the mediastinal staging of NSCLC, the results were 0.83 (0.02) and 0.96 (0.01) for dedicated PET and 0.81 (0.04) and 0.95 (0.02) for ganuna-camera PET. We conclude that dedicated PET could be a valuable tool in the diagnosis and staging of NSCLC. However, studies of populations with a lower prevalence of NSCLC are recommended.

AB - Lung cancer is the cause of 32% of all male cancer deaths and 25% of all female cancer deaths. Because the prognosis depends on early diagnosis and staging, continuous evaluation of the diagnostic tools available is important. The aim of this study was to assess the diagnostic value of dedicated positron emission tomography (PET) and gamma-camera PET in the diagnostic investigation of non-small-cell lung cancer (NSCLC). A systematic literature search was carried out in the MEDLINE and EMBASE databases and the Cochrane Controlled Trials Register. We identified 55 original works on the diagnostic performance of PET with fluorodeoxyglucose in the investigation of NSCLC. For diagnosis of NSCLC, the mean sensitivities and specificities were, respectively, 0.96 (SE 0.01) and 0.78 (0.03) for dedicated PET, and 0.92 (0.04) and 0.86 (0.04) for gamma-camera PET. In the mediastinal staging of NSCLC, the results were 0.83 (0.02) and 0.96 (0.01) for dedicated PET and 0.81 (0.04) and 0.95 (0.02) for ganuna-camera PET. We conclude that dedicated PET could be a valuable tool in the diagnosis and staging of NSCLC. However, studies of populations with a lower prevalence of NSCLC are recommended.

KW - Aged

KW - Carcinoma, Non-Small-Cell Lung

KW - Female

KW - Humans

KW - Lung Neoplasms

KW - Male

KW - Middle Aged

KW - Neoplasm Staging

KW - Sensitivity and Specificity

KW - Tomography, Emission-Computed

KW - Journal Article

KW - Review

U2 - 10.1016/S1470-2045(01)00555-1

DO - 10.1016/S1470-2045(01)00555-1

M3 - Journal article

C2 - 11902536

VL - 2

SP - 659

EP - 666

JO - Lancet Oncology

JF - Lancet Oncology

SN - 1470-2045

IS - 11

ER -

ID: 165882880